Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
New England Journal of Medicine · 2024
DOI: 10.1056/nejmc2402472 ↗Kurz gefasst
Leserbrief in der Zeitschrift New England Journal of Medicine, 2024. Verfasst von Talha Munir und 1 weiteren Autor:innen. Beteiligte Einrichtung: Leeds Cancer Centre, Leeds, United Kingdom peter.hillmen@nhs.net. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm, Residual, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 7 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Leeds Cancer Centre, Leeds, United Kingdom peter.hillmen@nhs.net.
Zitieren
APA
Munir, T., & Hillmen, P. (2024). Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. New England Journal of Medicine. https://doi.org/10.1056/nejmc2402472
Vancouver
Munir T, Hillmen P. Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. New England Journal of Medicine. 2024. doi:10.1056/nejmc2402472
BibTeX
@article{Munir2024,
author = {Munir, Talha and Hillmen, Peter},
title = {Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease},
journal = {New England Journal of Medicine},
year = {2024},
doi = {10.1056/nejmc2402472}
}
EUVIMED